albiglutide indications/contra

Stem definitionDrug idCAS RN
Glucagon-like Peptide (GLP) analogues 4927 782500-75-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • albiglutide
  • tanzeum
  • GSK-716155
  • GSK716155
  • albugon
A long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, with antihyperglycemic activity. Albiglutide is composed of a GLP-1 (7-36) dimer fused to recombinant human albumin. Upon subcutaneous administration, this agent has a half-life of 4-7 days and resists degradation by dipeptidyl peptidase-4 (DPP-4).
  • Molecular weight: 3284.64
  • Formula: C148H223N39O46
  • CLOGP:
  • LIPINSKI: None
  • HAC: 85
  • HDO: 49
  • TPSA: 1379.30
  • ALOGS:
  • ROTB: 108

Drug dosage:

DoseUnitRoute
5.70 mg P

Approvals:

DateAgencyCompanyOrphan
April 15, 2014 FDA GLAXOSMITHKLINE LLC

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Device use error 702.80 51.56 86 185 810 3384778
Device leakage 116.52 51.56 19 252 1301 3384287
Accidental exposure to product 109.94 51.56 22 249 4770 3380818
Product preparation error 104.19 51.56 16 255 740 3384848
Nausea 68.30 51.56 32 239 129613 3255975
Drug dose omission 64.51 51.56 22 249 38410 3347178
Underdose 63.73 51.56 15 256 6819 3378769
Vomiting 62.58 51.56 27 244 89504 3296084

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC A10BJ04 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Glucagon-like peptide-1 (GLP-1) analogues
FDA EPC N0000178480 GLP-1 Receptor Agonist
FDA MoA N0000020058 Glucagon-like Peptide-1 (GLP-1) Agonists

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Multiple endocrine neoplasia, type 2 contraindication 61808009 DOID:0050430
Medullary thyroid carcinoma contraindication 255032005 DOID:3973
History of medullary carcinoma of thyroid contraindication 429016002

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucagon-like peptide 1 receptor GPCR AGONIST EC50 9.70 SCIENTIFIC LITERATURE DRUG LABEL
Glucagon-like peptide 1 receptor GPCR AGONIST EC50 7.70 IUPHAR

External reference:

scroll-->
IDSource
7386 IUPHAR_LIGAND_ID
D08843 KEGG_DRUG
4033416 VUID
N0000190764 NUI
C2607479 UMLSCUI
5E7U48495E UNII
8829 INN_ID
DB09043 DRUGBANK_ID
CHEMBL2107841 ChEMBL_ID
C534611 MESH_SUPPLEMENTAL_RECORD_UI
1534763 RXNORM
30258 MMSL
d08251 MMSL
015507 NDDF
4033416 VANDF
703129009 SNOMEDCT_US
N0000190764 NDFRT
703905003 SNOMEDCT_US
122173812 PUBCHEM_CID
CHEBI:136045 CHEBI

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Tanzeum HUMAN PRESCRIPTION DRUG LABEL 1 0173-0866 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 mg SUBCUTANEOUS BLA 20 sections
Tanzeum HUMAN PRESCRIPTION DRUG LABEL 1 0173-0867 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg SUBCUTANEOUS BLA 20 sections